Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
MDVN [NASD]
Medivation, Inc.
Index- P/E333.11 EPS (ttm)0.28 Insider Own0.20% Shs Outstand76.79M Perf Week0.85%
Market Cap7.16B Forward P/E27.13 EPS next Y3.44 Insider Trans25.29% Shs Float75.47M Perf Month10.75%
Income23.70M PEG- EPS next Q0.82 Inst Own95.70% Short Float4.61% Perf Quarter25.23%
Sales391.90M P/S18.28 EPS this Y-1.80% Inst Trans-1.67% Short Ratio3.54 Perf Half Y36.16%
Book/sh1.87 P/B49.88 EPS next Y41.19% ROA5.80% Target Price102.00 Perf Year56.13%
Cash/sh3.78 P/C24.70 EPS next 5Y- ROE26.20% 52W Range48.15 - 97.90 Perf YTD46.15%
Dividend- P/FCF244.44 EPS past 5Y11.70% ROI-7.90% 52W High-4.73% Beta0.77
Dividend %- Quick Ratio4.80 Sales past 5Y85.00% Gross Margin- 52W Low93.71% ATR2.92
Employees433 Current Ratio4.80 Sales Q/Q111.30% Oper. Margin11.90% RSI (14)65.05 Volatility3.67% 2.92%
OptionableYes Debt/Eq1.50 EPS Q/Q957.10% Profit Margin6.00% Rel Volume1.15 Prev Close95.53
ShortableYes LT Debt/Eq1.50 EarningsAug 07 AMC Payout0.00% Avg Volume981.43K Price93.27
Recom1.80 SMA203.49% SMA5013.84% SMA20028.53% Volume1,130,166 Change-2.37%
12-Sep-14Reiterated Chardan Capital Markets Buy $100 → $122
11-Sep-14Reiterated Stifel Buy $89 → $112
08-Aug-14Reiterated UBS Buy $85 → $90
08-Aug-14Reiterated Stifel Buy $83 → $89
08-Aug-14Reiterated Brean Capital Buy $100 → $105
22-May-14Initiated Stifel Buy $81
16-Apr-14Initiated Canaccord Genuity Hold $60
17-Mar-14Reiterated Maxim Group Buy $92 → $112
03-Mar-14Reiterated UBS Buy $93 → $85
28-Feb-14Reiterated Maxim Group Buy $84 → $92
03-Feb-14Reiterated Chardan Capital Markets Buy $100
03-Feb-14Downgrade Needham Buy → Hold
29-Jan-14Reiterated Maxim Group Buy $75 → $84
29-Jan-14Reiterated Brean Capital Buy $72 → $100
29-Jan-14Reiterated Aegis Capital Buy $100 → $125
28-Jan-14Initiated CRT Capital Buy $88
10-Jan-14Reiterated Barclays Equal Weight $57 → $62
13-Nov-13Reiterated Maxim Group Buy $71 → $75
13-Nov-13Reiterated Barclays Equal Weight $53 → $57
28-Oct-13Reiterated Maxim Group Buy $66 → $71
15-Sep-14 07:05AM  Quarterly Changes to the NASDAQ Q-50 Index GlobeNewswire
12-Sep-14 05:24PM  Your first trade for Monday at CNBC
01:24PM  Your first trade for Monday at CNBC
12:58PM  [video] FMHR Final Trade: MDVN, C, NUE at CNBC
11-Sep-14 05:41PM  Medivation Eyes Blockbuster As Cancer Drug Gets An OK at Investor's Business Daily
05:35PM  Medivation-Astellas' Xtandi's Label Expanded by FDA Zacks
08:32AM  Stifel Raises Medivation Inc Price Target Benzinga
10-Sep-14 06:40PM  U.S. FDA approves expanded use of Medivation prostate cancer drug Reuters
05:21PM  U.S. FDA okays expanded use of Medivation prostate cancer drug Reuters
05:08PM  Medivation Resumes Trading After Xtandi Receives FDA Approval at Barrons.com
04:39PM  U.S. FDA Approves New Indication for the Use of XTANDI┬« (enzalutamide) Capsules for Patients with Metastatic Castration-Resistant Prostate Cancer PR Newswire
04:27PM  Medivation Still Halted as Xtandi Receives FDA Approval at Barrons.com
04:20PM  U.S. FDA Approves New Indication for the Use of XTANDI(R) (Enzalutamide) Capsules for Patients With Metastatic Castration-Resistant Prostate Cancer Marketwired
03:37PM  Medivation Prostate Cancer Drug Secures Expanded FDA Label at TheStreet
05-Sep-14 08:55AM  Biotech Stock Mailbag: Achillion, Ariad Revisited, Endocyte at TheStreet
03-Sep-14 11:50AM  Credit Suisse Positive on Some Biotechs, Very Cautious on Others at 24/7 Wall St.
25-Aug-14 04:10PM  Medivation Announces Participation at Upcoming Investor Conference Marketwired +5.04%
06:48AM  Can Medivation (MDVN) Run Higher on Strong Earnings Estimate Revisions? Zacks
19-Aug-14 04:25PM  Amgen (AMGN) Reports Encouraging Top-Line Data on AMG 416 Zacks
15-Aug-14 01:04PM  MEDIVATION, INC. Financials EDGAR Online Financials
11-Aug-14 11:10AM  Medivation Jumps on Q2 Earnings Beat, Outlook Encourages Zacks
06:36AM  Medivation (MDVN) Jumps: Stock Adds 7.5% in Session Zacks
08-Aug-14 12:03PM  Midday movers: Allergan, McDonald's, Sotheby's & More at CNBC +7.52%
12:03PM  Why Medivation (MDVN) Stock Is Gaining Today at TheStreet
11:55AM  Medivation Cancer Drug Fuels Beat, Swings To Profit at Investor's Business Daily
07-Aug-14 04:23PM  MEDIVATION, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:10PM  Medivation Reports Second Quarter Financial Results and Provides Corporate Update Marketwired
07:07AM  Q2 2014 Medivation, Inc. Earnings Release - After Market Close CCBN
29-Jul-14 06:54AM  [$$] Undervalued Biotech Stocks Beat the Index at Barrons.com
06:32AM  [$$] Beating the Benchmark With Undervalued Biotechs at Barrons.com
24-Jul-14 04:10PM  Medivation Announces Second Quarter 2014 Financial Results Teleconference on August 7, 2014 Marketwired
12:34PM  [video] Who's afraid of Janet Yellen? at CNBC
21-Jul-14 03:11PM  Astellas Up on Pipeline Update, Oncology in Focus (revised) Zacks
02:06PM  Medivation Significantly Undervalued, With Xtandi Weeks Away From Prostate Cancer Label Expansion at Seeking Alpha
16-Jul-14 02:50PM  Astellas Up on Pipeline Update, Oncology in Focus Zacks
14-Jul-14 02:36PM  Earnings Preview: Abbott Laboratories and Johnson & Johnson at Motley Fool
10-Jul-14 04:10PM  Medivation Announces Change in Executive Management Team Marketwired
02:03PM  Medivation Set To Go Higher As Prostate Cancer Drug Xtandi Quickly Approaches Blockbuster Status at Seeking Alpha
07-Jul-14 04:32PM  3 Reasons to Buy Medivation Inc. at Motley Fool
03-Jul-14 01:04PM  3 Stocks Underperforming Today In The Health Care Sector at TheStreet
02-Jul-14 05:58PM  Roche Holding Ltd Is Betting Billions on This New Blockbuster at Motley Fool
10:28AM  Aegis Capital Believes Seragon Deal Underscores Value In Medivation Benzinga
01-Jul-14 04:16PM  MEDIVATION, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Se EDGAR Online
25-Jun-14 06:24AM  Medivation Xtandi sales estimates raised at Citigroup at theflyonthewall.com
06:24AM  Medivation Xtandi sales estimates raised at Citigroup
24-Jun-14 11:34AM  Stratasys, 3D Systems And Medivation Lead Small-Cap Bets For Back Half Of 2014 at Forbes
11:34AM  Stratasys, 3D Systems And Medivation Lead Small-Cap Bets For Back Half Of 2014
23-Jun-14 09:33AM  UPDATE: Stifel Reiterates On Medivation Following Prostate Cancer Survey Benzinga
09:33AM  UPDATE: Stifel Reiterates On Medivation Following Prostate Cancer Survey
18-Jun-14 08:40AM  Moving Average Crossover Alert: Medivation (MDVN) Zacks
08:40AM  Moving Average Crossover Alert: Medivation (MDVN)
16-Jun-14 04:10PM  Medivation Again Voted Among Top Workplaces in the SF Bay Area Marketwired
04:10PM  Medivation Again Voted Among Top Workplaces in the SF Bay Area
11-Jun-14 04:10PM  Medivation Founder, President and Chief Executive Officer David Hung, M.D. Named an EY Entrepreneur Of The Year(TM) 2014 Award Winner in Northern California Marketwired
04:10PM  Medivation Founder, President and Chief Executive Officer David Hung, M.D. Named an EY Entrepreneur Of The Year(TM) 2014 Award Winner in Northern California
06-Jun-14 06:04PM  Why Wall Street Hates Dendreon Corp. at Motley Fool
04-Jun-14 07:45AM  Will Medivation (MDVN) Continue to Surge Higher? Zacks
07:45AM  Will Medivation (MDVN) Continue to Surge Higher?
07:08AM  Earnings Estimates Moving Higher for Medivation (MDVN): Time to Buy? Zacks
07:08AM  Earnings Estimates Moving Higher for Medivation (MDVN): Time to Buy?
01-Jun-14 09:01AM  New England Journal of Medicine Publishes Results from Phase 3 PREVAIL Trial of Enzalutamide in Men with Chemotherapy-Naive Metastatic Prostate Cancer Progressing Despite Androgen Deprivation Therapy PR Newswire
09:01AM  New England Journal of Medicine Publishes Results From Phase 3 PREVAIL Trial of Enzalutamide in Men With Chemotherapy-Naive Metastatic Prostate Cancer Progressing Despite Androgen Deprivation Therapy Marketwired
09:01AM  New England Journal of Medicine Publishes Results From Phase 3 PREVAIL Trial of Enzalutamide in Men With Chemotherapy-Naive Metastatic Prostate Cancer Progressing Despite Androgen Deprivation Therapy
09:01AM  New England Journal of Medicine Publishes Results from Phase 3 PREVAIL Trial of Enzalutamide in Men with Chemotherapy-Naive Metastatic Prostate Cancer Progressing Despite Androgen Deprivation Therapy
29-May-14 08:20AM  3 More Surges In Biotech Short Interest (AMGN, MDVN, PCYC) Benzinga
07:32AM  The Spectranetics (SPNC) Crumbles: Stock Falls by 8.1% Zacks
07:32AM  The Spectranetics (SPNC) Crumbles: Stock Falls by 8.1%
22-May-14 07:40AM  Medivation initiated with a Buy at Stifel at theflyonthewall.com
07:40AM  Medivation initiated with a Buy at Stifel
07:29AM  Coverage initiated on Medivation by Stifel Briefing.com
07:29AM  Coverage initiated on Medivation by Stifel
20-May-14 12:38PM  Why I'm Still Avoiding Dendreon at Motley Fool
16-May-14 01:04PM  MEDIVATION, INC. Financials EDGAR Online Financials
15-May-14 11:01AM  Options with decreasing implied volatility: GOGO MDVN FOSL NUAN DANG at theflyonthewall.com
14-May-14 05:01PM  Enzalutamide Data, Including Additional Results From the PREVAIL Trial, To be Presented at Upcoming ASCO Annual Meeting PR Newswire
05:01PM  Enzalutamide Data, Including Additional Results From the PREVAIL Trial, to Be Presented at Upcoming ASCO Annual Meeting Marketwired
11:11AM  Medivation Inc Stock Upgraded (MDVN) at TheStreet
12-May-14 02:52PM  Medivation Announces Participation at Upcoming Investor Conferences Marketwired
06:57AM  Strength Seen in Medivation (MDVN): Stock Up 8.5% Zacks
11-May-14 09:02AM  What You Need to Know About Medivation Inc.'s Results at Motley Fool
09-May-14 12:39PM  Why Medivation Inc. Shares Roared Higher at Motley Fool +8.52%
09:47AM  Medivation (MDVN) Is Today's Dead Cat Bounce Stock at TheStreet
09:10AM  Medivation Q1 Loss Wider Than Expected Zacks
08:43AM  Medivation guidance likely conservative, says Janney Capital at theflyonthewall.com
08-May-14 08:40PM  Medivation's (MDVN) CEO David Hung on Q1 2014 Results - Earnings Call Transcript at Seeking Alpha -5.50%
06:28PM  Medivation's Q1 Loss Shrinks by 50% as Xtandi Revenue Soars at Motley Fool
04:35PM  Medivation reports Q1 EPS (18c), consensus (9c) at theflyonthewall.com
04:21PM  MEDIVATION, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:10PM  Medivation Reports First Quarter Financial Results and Provides Corporate Update Marketwired
07:07AM  Q1 2014 Medivation, Inc. Earnings Release - After Market Close CCBN
07-May-14 09:02AM  Memorial Sloan-Kettering's Dr. Howard Scher Reaffirms Commitment to Lead Phase I Trials for AV Therapeutics' Prostate Cancer Drug GlobeNewswire
08:34AM  Biotech Stock Roundup: Endocyte Tumbles & Merrimack Soars on Pipeline News Zacks
06-May-14 09:22AM  Tuesdays Top Health Care Stories: Bayer, Merck, Medivation, and AstraZeneca at Motley Fool
07:00AM  Astellas and Medivation Receive Priority Review from FDA for XTANDI┬« (Enzalutamide) Capsules In Chemotherapy-Naive Advanced Prostate Cancer PR Newswire
07:00AM  Astellas and Medivation Receive Priority Review From FDA for XTANDI(R) (Enzalutamide) Capsules in Chemotherapy-Naive Advanced Prostate Cancer Marketwired
06:57AM  Why Earnings Season Could Be Great for Medivation (MDVN) Zacks
02-May-14 08:04AM  The Zacks Analyst Blog Highlights: Gilead, Acorda Therapeutics, Hyperion Therapeutics and Medivation Zacks
25-Apr-14 11:48AM  Joel Ackerman, the CEO of Champions Oncology, Inc. (CSBR), Interviews with The Wall Street Transcript Wall Street Transcript
24-Apr-14 06:31PM  3 Drugs Johnson & Johnsons Investors Better Know About at Motley Fool
05:25PM  Medivation Signs Deal with OncoFusion Therapeutics Zacks
Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients. The company also conducts various trials of enzalutamide in earlier prostate cancer disease states, including the Phase III PREVAIL trial in patients with mCRPC who have not received chemotherapy; and in patients with breast cancer. It has collaboration agreement with Astellas Pharma, Inc. for the development, manufacture, and commercialization of XTANDI. The company is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Seely LynnChief Medical OfficerSep 09Option Exercise10.5920,000211,70079,022Sep 11 06:04 PM
Seely LynnChief Medical OfficerSep 09Sale94.6020,0001,892,01659,022Sep 11 06:04 PM
Seely LynnChief Medical OfficerAug 27Option Exercise10.5914,300151,36673,322Aug 28 07:54 PM
Seely LynnChief Medical OfficerAug 27Sale89.6114,3001,281,42359,022Aug 28 07:54 PM
Seely LynnChief Medical OfficerAug 26Option Exercise10.595,70060,33564,722Aug 28 07:54 PM
Seely LynnChief Medical OfficerAug 26Sale88.955,700507,03259,022Aug 28 07:54 PM
Seely LynnChief Medical OfficerAug 13Option Exercise8.3920,000167,82579,022Aug 14 08:00 PM
Seely LynnChief Medical OfficerAug 13Sale83.6220,0001,672,45659,022Aug 14 08:00 PM
Seely LynnChief Medical OfficerAug 12Option Exercise9.3912,500117,31371,522Aug 12 08:49 PM
Seely LynnChief Medical OfficerAug 12Sale84.0112,5001,050,12559,022Aug 12 08:49 PM
Seely LynnChief Medical OfficerAug 08Option Exercise9.3913,000122,00572,022Aug 12 08:49 PM
Seely LynnChief Medical OfficerAug 08Sale82.0613,0001,066,82159,022Aug 12 08:49 PM
Seely LynnChief Medical OfficerJul 22Option Exercise6.747,50050,51366,522Jul 23 06:19 PM
Seely LynnChief Medical OfficerJul 22Sale73.967,500554,71059,022Jul 23 06:19 PM
Seely LynnChief Medical OfficerJul 02Option Exercise9.3912,000112,62071,022Jul 07 07:35 PM
Seely LynnChief Medical OfficerJul 02Sale79.0212,000948,19459,022Jul 07 07:35 PM
Seely LynnChief Medical OfficerJun 18Option Exercise6.747,50050,51366,522Jun 19 04:35 PM
Seely LynnChief Medical OfficerJun 18Sale75.007,500562,53059,022Jun 19 04:35 PM
Seely LynnChief Medical OfficerJun 03Option Exercise6.747,50050,51366,522Jun 19 04:35 PM
Seely LynnChief Medical OfficerJun 03Sale74.507,500558,76059,022Jun 19 04:35 PM
Machado Clarence PatrickChief Business Officer and CFOFeb 18Option Exercise10.5940,000423,40070,830Feb 19 04:58 PM
Machado Clarence PatrickChief Business Officer and CFOFeb 18Sale82.7940,0003,311,64630,830Feb 19 04:58 PM
Machado Clarence PatrickChief Business Officer and CFOFeb 11Option Exercise10.5940,000423,40070,830Feb 12 05:34 PM
Machado Clarence PatrickChief Business Officer and CFOFeb 11Sale80.8340,0003,233,12130,830Feb 12 05:34 PM
Machado Clarence PatrickChief Business Officer and CFOFeb 05Option Exercise10.5940,000423,40070,830Feb 06 05:24 PM
Machado Clarence PatrickChief Business Officer and CFOFeb 05Sale73.4640,0002,938,57430,830Feb 06 05:24 PM
Machado Clarence PatrickChief Business Officer and CFOJan 28Option Exercise10.5940,000423,40070,830Jan 29 07:33 PM
Machado Clarence PatrickChief Business Officer and CFOJan 28Sale75.4340,0003,017,12230,830Jan 29 07:33 PM
Hung DavidPresident and CEOJan 27Option Exercise5.88150,000882,0001,100,204Jan 28 05:39 PM
Hung DavidPresident and CEOJan 27Sale73.50150,00011,025,357950,204Jan 28 05:39 PM
Machado Clarence PatrickChief Business Officer and CFOJan 21Option Exercise10.5940,000423,40070,830Jan 23 07:24 PM
Machado Clarence PatrickChief Business Officer and CFOJan 21Sale76.2940,0003,051,62730,830Jan 23 07:24 PM
Rhodes Jennifer JGC & Chief Compliance OfficerJan 21Sale76.2814,0001,067,9496,000Jan 23 07:23 PM